In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines

Clinical and Translational Oncology

Volumn 13, Issue 1, 2011, Pages 43-49

  Fiebiger, Wolfgang ^a   Olszewski, Ulrike ^b   Ulsperger, Ernst ^b   Geissler, Klaus ^b   Hamilton, Gerhard ^b,c  

^a St Poelten Hospital   (Austria)

^b Ludwig Boltzmann Cluster of Translational Oncology   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Carcinoid; Chemosensitivity; Dichloroacetate; Drug resistance; Picoplatin; Platinum complex; Satraplatin

Indexed keywords

CAMPTOTHECIN; CARBOPLATIN; CIS AMMINEDICHLORO(CYCLOHEXYLAMINE)DIHYDROXOPLATINUM; DACARBAZINE; DICHLOROACETIC ACID; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; MITOMYCIN C; OXALIPLATIN; OXOPLATIN; PACLITAXEL; PICOPLATIN; PLATINUM AMMINE CYCLOHEXYLAMINE DICHLORIDE; PLATINUM COMPLEX; SATRAPLATIN; TETRAZOLIUM; TOPOTECAN; VINBLASTINE;

APOPTOSIS; CANCER CELL CULTURE; CARCINOID; CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CHEMOSENSITIVITY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LUNG CANCER; SPHEROID CELL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOID TUMOR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXINS; DICHLOROACETATE; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PLATINUM COMPOUNDS;

EID: 79551519970     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-011-0615-z     Document Type: Conference Paper

References (56)

1. K. Öberg 2003 Diagnosis and treatment of carcinoid tumors Expert Rev Anticancer Ther 3 863 877 10.1586/14737140.3.6.863 14686708
2. I.M. Modlin M. Kidd I. Latich, et al. 2005 Current status of gastrointestinal carcinoids Gastroenterology 128 1717 1751 10.1053/j.gastro. 2005.03.038 15887161 (Pubitemid 40692562)
3. S.N. Pinchot K. Holen R.S. Sippel H. Chen 2008 Carcinoid tumors Oncologist 13 1255 1269 1:CAS:528:DC%2BD1MXhvV2nurs%3D 10.1634/theoncologist. 2008-0207 19091780
4. J.M. Zuetenhorst B.G. Taal 2005 Metastatic carcinoid tumors: a clinical review Oncologist 10 123 131 10.1634/theoncologist.10-2-123 15709214 (Pubitemid 40261951)
5. D. Granberg K. Oberg 2005 Neuroendocrine tumours Cancer Chemother Biol Response Modif 22 471 483 16110625
6. C. Capella P.U. Heitz H. Hofler, et al. 1995 Revised classification of neuroendocrine tumors of the lung, pancreas and gut Virchows Arch 425 547 560 1:STN:280:DyaK2M3htFaqtg%3D%3D 10.1007/BF00199342 7697211
7. W.H. Warren V.E. Gould L.P. Faber, et al. 1985 Neuroendocrine neoplasms of the bronchopulmonary tract: a classification of the spectrum of carcinoid to small cell carcinoma and intervening variants J Thorac Cardiovasc Surg 89 819 825 1:STN:280:DyaL2M3ht1eitQ%3D%3D 2582209
8. U. Plockinger G. Rindi R. Arnold, et al. 2004 European Neuroendocrine Tumour Society: guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS) Neuroendocrinology 80 394 424 1:STN:280:DC%2BD2M3nt1Chtw%3D%3D 10.1159/000085237 15838182 (Pubitemid 40874886)
9. K. Öberg B. Eriksson 2005 Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours Best Pract Res Clin Endocrinol Metab 19 265 276 10.1016/j.beem.2004.11.016 15763700 (Pubitemid 40347816)
10. B. Dousset O. Saint-Marc J. Pitre, et al. 1996 Metastatic endocrine tumors: medical treatment, surgical resection and liver transplantation World J Surg 20 908 915 1:STN:280:DyaK28vislansA%3D%3D 10.1007/s002689900138 8678970 (Pubitemid 26281922)
11. M. Raderer A. Kurtaran M. Leimer, et al. 2000 Value of peptide receptor scintigraphy using (123) I-vasoactive intestinal peptide and (111)In-DTPAD-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998 J Clin Oncol 18 1331 1336 1:CAS:528: DC%2BD3cXit12ltLY%3D 10715305
12. F.M. Smolle-Juttner H. Popper H. Klemen, et al. 1993 Clinical features and therapy of "typical" and "atypical" bronchial carcinoid tumors (grade 1 and grade 2 neuroendocrine carcinoma) Eur J Cardiothorac Surg 7 121 125 1:STN:280:DyaK3s3htlGitw%3D%3D 10.1016/1010-7940(93)90033-8 8384862
13. C.H. Marty-Ane V. Costes J.L. Pujol, et al. 1995 Carcinoid tumors of the lung: do atypical features require aggressive management? Ann Thorac Surg 59 78 83 1:STN:280:DyaK2M7hvVWksA%3D%3D 10.1016/0003-4975(94)00630-P 7818364
14. C.G. Moertel W.G. Sauer M.B. Dockerty A.H. Baggenstoss 1961 Life history of the carcinoid tumor of the small intestine Cancer 14 901 912 1:STN:280:DyaF3c%2FptFOitQ%3D%3D 10.1002/1097-0142(196109/10)14:5<901::AID- CNCR2820140502>3.0.CO;2-Q 13771655
15. J.D. Goodwin 1975 Carcinoid tumors: an analysis of 2837 cases Cancer 36 560 569 10.1002/1097-0142(197508)36:2<560::AID-CNCR2820360235>3.0.CO;2-4
16. E.M. Bertino P.D. Confer J.E. Colonna, et al. 2009 Pulmonary neuroendocrine/carcinoid tumors: a review article Cancer 115 4434 4441 10.1002/cncr.24498 19562772
17. C.G. Moertel 1983 Treatment of the carcinoid tumor and the malignant carcinoid syndrome J Clin Oncol 1 727 740 1:STN:280:DyaL2c7jslOltg%3D%3D 6199469
18. W. Sun S. Lipsitz P. Catalano, et al. 2005 Phase II/III Study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281 J Clin Oncol 23 4897 4904 1:CAS:528: DC%2BD2MXpsFWmt7c%3D 10.1200/JCO.2005.03.616 16051944 (Pubitemid 46223995)
19. J.E. Dowell 2010 Small cell lung cancer: are we making progress? Am J Med Sci 339 68 76 10.1097/MAJ.0b013e3181bccef5 19996730
20. N. Shah D.S. Dizon 2009 New-generation platinum agents for solid tumors Future Oncol 5 33 42 1:CAS:528:DC%2BD1MXitlyltbs%3D 10.2217/14796694.5.1.33 19243296
21. S. Dhar S.J. Lippard 2009 Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate Proc Natl Acad Sci U S A 106 22199 22204 1:CAS:528:DC%2BC3cXmtlWruw%3D%3D 10.1073/pnas.0912276106 20007777
22. C.D. Chong C.J. Logothetis N. Savaraj, et al. 1988 The correlation of vinblastine pharmacokinetics to toxicity in testicular cancer patients J Clin Pharmacol 28 714 718 1:STN:280:DyaL1M7gvFKnuw%3D%3D 3216038
23. E.K. Rowinsky P.J. Burke J.E. Karp, et al. 1989 Phase I and pharmacodynamic study of taxol in refractory acute leukemias Cancer Res 49 4640 4647 1:STN:280:DyaL1Mzgtl2jsw%3D%3D 2568175
24. M.J. Dennis J.H. Beijnen L.B. Grochow L.J.C. van Warderdam 1997 An overview of the clinical pharmacology of topotecan Semin Oncol 24 12 18S
25. D.H. Ho R. Pazdur W. Covington, et al. 1998 Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2′-tetrahydrofuryl)-5-fluorouracil Clin Cancer Res 4 2085 2088 1:CAS:528:DyaK1cXmslCjs7w%3D 9748123
26. J. Wihlm J.M. Limacher D. Leveque, et al. 1997 Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients Bull Cancer 84 603 608 1:STN:280:DyaK2svktFKntg%3D%3D 9295863
27. N. Touroutoglou D. Gravel M.N. Raber, et al. 1998 Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors Ann Oncol 9 1003 1008 1:STN:280:DyaK1M%2FjsFCgtw%3D%3D 10.1023/A:1008487932384 9818075 (Pubitemid 28496710)
28. K.T. Kivisto K. Villikka L. Nyman, et al. 1998 Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampicin Clin Pharmacol Ther 64 648 654 1:CAS:528:DyaK1MXjslWgsg%3D%3D 10.1016/S0009-9236(98)90055-8 9871429 (Pubitemid 29011384)
29. A. Bonetti T. Franceschi P. Apostoli, et al. 1995 Cisplatin pharmacokinetics using a five-day schedule during repeated courses of chemotherapy in germ cell tumors Ther Drug Monit 17 25 32 1:CAS:528: DyaK2MXkt1eqsLw%3D 10.1097/00007691-199502000-00005 7725373
30. M.A. Graham G.F. Lockwood D. Greenslade, et al. 2000 Clinical pharmacokinetics of oxaliplatin: a critical review Clin Cancer Res 6 1205 1218 1:CAS:528:DC%2BD3cXjtVOqsbk%3D 10778943
31. S. Oguri T. Sakakibara H. Mase, et al. 1988 Clinical pharmacokinetics of carboplatin J Clin Pharmacol 28 208 215 1:CAS:528:DyaL1cXlvVejsbo%3D 3283185
32. R.B. Schilcher J.D. Young V. Ratanatharathorn, et al. 1984 Clinical pharmacokinetics of highdose mitomycin C Cancer Chemother Pharmacol 13 186 190 1:CAS:528:DyaL2MXhsFI%3D 10.1007/BF00269026 6386213
33. A.B. Adolphe E.D. Glasofer W.M. Troetel, et al. 1975 Fate of streptozotocin (NSC-85998) in patients with advanced cancer Cancer Chemother Rep 9 547 556
34. K. Hande M. Messenger J. Wagner, et al. 1999 Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug application Clin Cancer Res 5 2742 2747 1:CAS:528:DyaK1MXntlGltb8%3D 10537337
35. G.G. Chabot L.E. Flaherty M. Valdivieso L.H. Baker 1990 Alteration of DTIC pharmacokinetics after interleukin-2 administration in melanoma patients Cancer Chemother Pharmacol 27 157 160 1:STN:280:DyaK3M%2FmsVymsg%3D%3D 10.1007/BF00689102 2249333
36. L.K. Kvols C.G. Moertel M.J. O'Connell, et al. 1986 Treatment of the malignant carcinoid evaluation of a long-acting somatostatin analog N Engl J Med 315 663 666 1:STN:280:DyaL28zhtFSrsQ%3D%3D 10.1056/NEJM198609113151102 2427948
37. P.F. Engstrom P.T. Lavin C.G. Moertel, et al. 1984 Streptozotocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor J Clin Oncol 8 865 890
38. E. Vilar R. Salazar J. Pérez-García, et al. 2007 Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors Endocr Relat Cancer 14 221 23 1:CAS:528:DC%2BD2sXhtV2lsrzM 10.1677/ERC-06-0074 17639039 (Pubitemid 47242624)
39. M. García-Yuste J.M. Matilla A. Cueto, et al. 2007 Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung Eur J Cardiothorac Surg 31 192 197 10.1016/j.ejcts.2006.11.031 17196822 (Pubitemid 46150082)
40. G. Giaccone J. Battey A.F. Gazdar, et al. 1992 Neuromedin B is present in lung cancer cell lines Cancer Res 52 2732s 2736s 1:CAS:528:DyaK38XktVGhsLY%3D 1563005
41. L. Saltz G. Lauwers J. Wiseberg D. Kelsen 1993 A phase II trial of carboplatin in patients with advanced APUD tumors Cancer 72 619 622 1:STN:280:DyaK3szgs1Kitw%3D%3D 10.1002/1097-0142(19930715)72:2<619::AID- CNCR2820720247>3.0.CO;2-E 8391382
42. B.G. Skov B. Holm A. Erreboe, et al. 2010 ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival J Thorac Oncol 5 453 459 10.1097/JTO.0b013e3181ca063b 20104194
43. K. Kelly 2000 New chemotherapy agents for small cell lung cancer Chest 117 156 162S 10.1378/chest.117.4-suppl-1.156S
44. B.A. Teicher 2008 Newer cytotoxic agents: attacking cancer broadly Clin Cancer Res 14 1610 1617 1:CAS:528:DC%2BD1cXjtlejtrw%3D 10.1158/1078-0432.CCR-07- 2249 18347161 (Pubitemid 351469444)
45. S.M. Ansell H.C. Pitot P.A. Burch, et al. 2001 A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors Cancer 91 1543 1548 1:CAS:528:DC%2BD3MXjt1Srsbg%3D 10.1002/1097-0142(20010415)91: 8<1543::AID-CNCR1163>3.0.CO;2-N 11301403 (Pubitemid 32319266)
46. L. Iyer M.J. Ratain 1998 Clinical pharmacology of camptothecins Cancer Chemother Pharmacol 42 S31 S43 1:CAS:528:DyaK1cXlvV2mur4%3D 10.1007/ s002800051077 9750027
47. G. Catimel G.G. Chabot J.P. Guastalla, et al. 1995 Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors Ann Oncol 6 133 140 1:STN:280:DyaK2Mzgs1Cjug%3D%3D 7786821
48. J.M. Lyons 3rd J. Abergel J.L. Thomson, et al. 2009 In vitro chemoresistance testing in well-differentiated carcinoid tumors Ann Surg Oncol 16 649 655 10.1245/s10434-008-0261-z 19130141
49. A.T. Porter M.J. Ostrowski 1988 Successful treatment of malignant carcinoid tumour with intravenous cisplatinum Eur J Surg Oncol 14 703 704 1:STN:280:DyaL1M%2Flt12isQ%3D%3D 3192008
50. U. Olszewski G. Hamilton 2010 A better platinum-based anticancer drug yet to come? Anticancer Agents Med Chem 10 293 301 1:CAS:528:DC%2BC3cXmsVams7w%3D 20187870
51. M. Wasilewski L. Scorrano 2009 The changing shape of mitochondrial apoptosis Trends Endocrinol Metab 20 287 294 1:CAS:528:DC%2BD1MXps1Sqsrg%3D 10.1016/j.tem.2009.03.007 19647447
52. E.D. Michelakis L. Webster J.R. Mackey 2008 Dichloroacetate (DCA) as a potential metabolictargeting therapy for cancer Br J Cancer 99 989 994 1:CAS:528:DC%2BD1cXhtFyqt7vN 10.1038/sj.bjc.6604554 18766181
53. R.C. Sun M. Fadia J.E. Dahlstrom, et al. 2010 Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo Breast Cancer Res Treat 120 253 260 1:CAS:528: DC%2BC3cXntlaruw%3D%3D 10.1007/s10549-009-0435-9 19543830
54. G.A. Otterson L. Wang X. Wu, et al. 2008 Effect of dichloroacetate in combination with chemotherapy on human lung cancer cells J Clin Oncol 26S 14637
55. S. Dhar S.J. Lippard 2009 Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate Proc Natl Acad Sci U S A 106 22199 22204 1:CAS:528:DC%2BC3cXmtlWruw%3D%3D 10.1073/pnas.0912276106 20007777
56. T. Li I. Schultz D.A. Keys, et al. 2008 Quantitative evaluation of dichloroacetic acid kinetics in human: a physiologically based pharmacokinetic modeling investigation Toxicology 245 35 48 1:CAS:528:DC%2BD1cXitlKrtLY%3D 10.1016/j.tox.2007.12.010 18242812